Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTQ5082 and Midazolam Drug-Drug Interaction Study
NCT07745439Phase 1Not yet recruiting
- Sponsor
- Third Xiangya Hospital, Central South University
- Start
- Jul 2026
- Primary completion
- Jul 2026
01
Overview
Phase 1, open-label, single-arm trial of NTQ5082, sponsored by Third Xiangya Hospital, Central South University. Primary endpoints: Maximum Plasma Concentration at Day 11, Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration at Day 11 and 1 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
NTQ5082
Beyond the preview
Go deeper on NCT07745439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07745439.